Back to search

Peptide record

TPDB08309

Antibacterial Anticancer Toxicity standard

16 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB08309

Activity

Antibacterial Anticancer Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 Peptipedia

Sequence_Type

standard

Has_Modification No

Description A 16-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3 and Peptipedia, with an available 3D structural model.

Sequence

RRIRPRPPRLPRPRPR

FASTA

>TPDB08309|Antibacterial;Anticancer;Toxicity|length=16
RRIRPRPPRLPRPRPR

Formula C90H162N40O17

Absent Amino Acids ANDCEQGHKMFSTWYV

Common Amino Acids R

Mass 2076.53

PI 13.25

Basic Residues 8

Acidic Residues 0

Hydrophobic Residues 2

Net Charge +8

Boman Index 8.31

Hydrophobicity -2.331

Aliphatic Index 48.75

Half Life

Mammalian: 1 hour Yeast: 2 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 0

number

Amino Acid Distribution

A: 0 R: 8 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 1 K: 0 M: 0 F: 0 P: 6 S: 0 T: 0 W: 0 Y: 0 V: 0

Length

Formula

C90H162N40O17

Mass

2076.53

13.25

Net Charge

Boman Index

8.31

Hydrophobicity

-2.331

Evidence 1 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 2 µM

Target

Target Organism Escherichia coli ATCC 25922 or ML-35

Source & Reference

Database Source NA

Other

Evidence Text

active against E. coli ATCC 25922 or ML-35 (MIC 2 uM), S. enterica serovar Typhimurium ATCC 14028 (MIC 1 uM), S. marcescens ATCC8100 (MIC 8 uM)

Evidence 2 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 1 µM

Target

Target Organism S. enterica serovar Typhimurium ATCC 14028

Source & Reference

Database Source NA

Other

Evidence Text

active against E. coli ATCC 25922 or ML-35 (MIC 2 uM), S. enterica serovar Typhimurium ATCC 14028 (MIC 1 uM), S. marcescens ATCC8100 (MIC 8 uM), K. pneumoniae 13 clinical strains (MIC 1-16 uM), A. b

Evidence 3 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 8 µM

Target

Target Organism S. marcescens ATCC8100

Source & Reference

Database Source NA

Other

Evidence Text

li ATCC 25922 or ML-35 (MIC 2 uM), S. enterica serovar Typhimurium ATCC 14028 (MIC 1 uM), S. marcescens ATCC8100 (MIC 8 uM), K. pneumoniae 13 clinical strains (MIC 1-16 uM), A. baumannii 12 clinical strains (MIC 0

Evidence 4 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 1-16 µM

Target

Target Organism Klebsiella pneumoniae 13 clinical strains

Source & Reference

Database Source NA

Other

Evidence Text

S. enterica serovar Typhimurium ATCC 14028 (MIC 1 uM), S. marcescens ATCC8100 (MIC 8 uM), K. pneumoniae 13 clinical strains (MIC 1-16 uM), A. baumannii 12 clinical strains (MIC 0.5-64 uM), P. aeruginosa 20 clinical strains (MIC

Evidence 5 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 0.5-64 µM

Target

Target Organism A. baumannii 12 clinical strains

Source & Reference

Database Source NA

Other

Evidence Text

uM), S. marcescens ATCC8100 (MIC 8 uM), K. pneumoniae 13 clinical strains (MIC 1-16 uM), A. baumannii 12 clinical strains (MIC 0.5-64 uM), P. aeruginosa 20 clinical strains (MIC 64->128 uM), B.cepacia 10 clinical strains (MIC >

Evidence 6 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 64->128 µM

Target

Target Organism Pseudomonas aeruginosa 20 clinical strains

Source & Reference

Database Source NA

Other

Evidence Text

niae 13 clinical strains (MIC 1-16 uM), A. baumannii 12 clinical strains (MIC 0.5-64 uM), P. aeruginosa 20 clinical strains (MIC 64->128 uM), B.cepacia 10 clinical strains (MIC > 128 uM), S.aureus ATCC 25923 (MIC >128 uM).

Evidence 7 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement >128 µM

Target

Target Organism S.aureus ATCC 25923

Source & Reference

Database Source NA

Other

Evidence Text

inosa 20 clinical strains (MIC 64->128 uM), B.cepacia 10 clinical strains (MIC > 128 uM), S.aureus ATCC 25923 (MIC >128 uM).

Evidence 8 Activity

Activity

Activity Endpoint <3% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 100 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

<3% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Effects of Lipidation on a Proline-Rich Antibacterial Peptide. | Int J Mol Sci | 2021

Evidence 9 Activity

Activity

Activity Endpoint 25% Cytotoxicity

Detail Source Activity Toxicity

Activity Measurement 25 µM

Toxicity Type Cytotoxic

Toxicity Raw

25% Cytotoxicity | 25 | µM | target cell: Human keratinocytes HaCat

Target

Target Cell Human keratinocytes HaCat

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Effects of Lipidation on a Proline-Rich Antibacterial Peptide. | Int J Mol Sci | 2021

Evidence 10 Activity

Activity

Activity Endpoint 82% Cytotoxicity

Detail Source Activity Toxicity

Activity Measurement 100 µM

Toxicity Type Cytotoxic

Toxicity Raw

82% Cytotoxicity | 100 | µM | target cell: Human keratinocytes HaCat

Target

Target Cell Human keratinocytes HaCat

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Effects of Lipidation on a Proline-Rich Antibacterial Peptide. | Int J Mol Sci | 2021

Evidence 11 Activity

Activity

Activity Endpoint 45% Cytotoxicity

Detail Source Activity Toxicity

Activity Measurement 100 µM

Toxicity Type Cytotoxic

Toxicity Raw

45% Cytotoxicity | 100 | µM | target cell: Human keratinocytes HaCat

Target

Target Cell Human keratinocytes HaCat

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Effects of Lipidation on a Proline-Rich Antibacterial Peptide. | Int J Mol Sci | 2021